Male gynecomastia

Mayo Clinic Proceedings

Volumn 84, Issue 8, 2009, Pages 672-

  Haynes, Bridgett A ^a   Mookadam, Farouk ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SPIRONOLACTONE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG WITHDRAWAL; GYNECOMASTIA; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MALE; PHYSICAL EXAMINATION;

EID: 68149126335     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/84.8.672     Document Type: Article

References (6)

1. Mosenkis A, Townsend RR. Gynecomastia and antihypertensive therapy. J Clin Hypertens (Greenwich). 2004;6(8)469-470.
2. Prisant LM, Chin E. Gynecomastia and hypertension. J Clin Hypertens (Greenwich). 2005;7(4):245-248.
3. Pitt B, Zannad F, Remme WJ, et al; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709-717.
4. Chapman N, Dobson J, Wilson S, et al; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49(4):839-845. Epub 2007 Feb 19.
5. Rose LI, Underwood RH, Newmark SR, Kisch ES, Williams GH. Pathophysiology of spironolactone-induced gynecomastia. Ann Intern Med. 1977;87(4):398-403.
6. Pitt B, Remme W, Zannad F, et al; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [published correction appears in N Engl J Med. 2003;348(22):2271]. N Engl J Med. 2003;348(14):1309-1321. Epub 2003 Mar 31.